Nuveen
ATEX icon

Nuveen’s Anterix ATEX Stock Holding History

Nuveen’s Portfolio ATEX Stock Details ATEX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.69M Buy
35,798
+12,923
+56% +$758K ﹤0.01% 2271
2026
Q1 		$874K Sell
22,875
-30,280
-57% -$958K ﹤0.01% 2638
2025
Q4 		$1.16M Buy
53,155
+30,420
+134% +$632K ﹤0.01% 2552
2025
Q3 		$488K Sell
22,735
-173,985
-88% -$3.9M ﹤0.01% 2902
2025
Q2 		$5.05M Sell
196,720
-115
-0.1% -$3.37K ﹤0.01% 1879
2025
Q1 		$7.2M Buy
196,835
+11,262
+6% +$387K ﹤0.01% 1734
2024
Q4 		$5.69M Buy
185,573
+38,770
+26% +$1.29M ﹤0.01% 1924
2024
Q3 		$5.53M Buy
146,803
+112,696
+330% +$4.34M ﹤0.01% 1948
2024
Q2 		$1.35M Hold
34,107
– – ﹤0.01% 2575
2024
Q1 		$1.15M Hold
34,107
– – ﹤0.01% 2642
2023
Q4 		$1.14M Buy
34,107
+275
+0.8% +$8.87K ﹤0.01% 2678
2023
Q3 		$1.06M Sell
33,832
-8,339
-20% -$262K ﹤0.01% 2551
2023
Q2 		$1.34M Hold
42,171
– – ﹤0.01% 2526
2023
Q1 		$1.39M Sell
42,171
-3,461
-8% -$113K ﹤0.01% 2478
2022
Q4 		$1.47M Sell
45,632
-6,598
-13% -$225K ﹤0.01% 2514
2022
Q3 		$1.86M Buy
52,230
+9,839
+23% +$408K ﹤0.01% 2428
2022
Q2 		$1.74M Sell
42,391
-86,956
-67% -$4.22M ﹤0.01% 2504
2022
Q1 		$7.45M Sell
129,347
-13,915
-10% -$761K ﹤0.01% 1825
2021
Q4 		$8.01M Sell
143,262
-3,892
-3% -$236K ﹤0.01% 1823
2021
Q3 		$8.13M Sell
147,154
-2,715
-2% -$159K ﹤0.01% 1922
2021
Q2 		$8.99M Buy
149,869
+59,927
+67% +$3M ﹤0.01% 1932
2021
Q1 		$4.24M Buy
89,942
+22,228
+33% +$915K ﹤0.01% 2240
2020
Q4 		$2.55M Sell
67,714
-31,973
-32% -$1.05M ﹤0.01% 2391
2020
Q3 		$3.26M Sell
99,687
-7,357
-7% -$311K ﹤0.01% 2135
2020
Q2 		$4.85M Buy
107,044
+25,455
+31% +$1.3M ﹤0.01% 1912
2020
Q1 		$3.73M Buy
81,589
+6,510
+9% +$295K ﹤0.01% 1878
2019
Q4 		$3.24M Sell
75,079
-27,680
-27% -$1.13M ﹤0.01% 2215
2019
Q3 		$3.72M Buy
102,759
+53,265
+108% +$2.25M ﹤0.01% 2118
2019
Q2 		$2.33M Buy
+49,494
New +$2.09M ﹤0.01% 2363

Other funds holding ATEX

OCAM
Owl Creek Asset Management New York $1.21B AUM 169.99% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $2.34B AUM 46.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PM
Plustick Management Charlottesville, Virginia $269M AUM 340.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return

Nuveen's ATEX Position: Q2 2026 in Review

Nuveen increased its Anterix (ATEX) stake by 56% in Q2 2026, buying an estimated $758K and bringing the position to 35,798 shares worth $3.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2271.

Nuveen first reported a position in ATEX in Q2 2019 and has held it in 29 quarters since. The position peaked at $8.99M in Q2 2021. 172 funds tracked by Wall St. Rank hold ATEX as of Q2 2026.

  • Nuveen held 35,798 shares of Anterix worth $3.69M as of Q2 2026.
  • Nuveen bought 12,923 Anterix shares in Q2 2026, an estimated $758K.
  • Anterix made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2271 holding.
  • Nuveen first reported a position in Anterix in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Anterix position peaked at $8.99M in Q2 2021.
  • 172 funds tracked by Wall St. Rank held Anterix as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.